Skip to main content
An official website of the United States government
Technology ID
TAB-4010

Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations

E-Numbers
E-028-2015-0
E-028-2015-1
Lead Inventors
Wang, Qiong
Co-Inventors
Yang, James
Yu, Zhiya
Applications
Therapeutics
Therapeutic Areas
Oncology
Development Stages
Discovery
Lead IC
NCI
ICs
NCI

Several malignancies associated with a poor prognosis such as lung, pancreatic and colorectal cancers frequently harbor constitutively active KRAS mutants, which play a pivotal role in oncogenesis.  Currently, there are no potentially curative treatments against most mutant KRAS harboring cancers once they become metastatic and unresectable.  Despite intensive efforts to develop potent mutant KRAS inhibitors, none have shown a significant improvement to patients.

Researchers at NCI’s Surgery Branch have used their expertise in T-cell based therapies to develop a T cell receptor (TCR) that specifically recognizes G12D KRAS, a common driver of oncogenesis.  This invention offers an alternative therapy to direct inhibition of mutant KRAS that has been demonstrative to be an effective treatment for advanced melanoma, lymphoma and sarcomas.  The inventors have demonstrated that lymphocytes expressing the engineered TCR selectively target pancreatic G12D KRAS cells.

The NCI seeks co-development or licensing partners to extend the research toward in vivo efficacy testing and clinical trials.

Competitive Advantages:

  • Proven therapeutic strategy for targeting cancers that harbor mutant target proteins
  • Alternative strategy to previously unsuccessful small molecule KRAS inhibitors

Commercial Applications:

  • T-cell therapy to treat a variety of cancers that harbor KRAS mutations, in particular, G12D mutation
  • Therapy for cancers that harbor additional constitutively active KRAS mutations

 

Request More Info

Licensing Contacts
Burke, Andrew
burkear@mail.nih.gov

Related Inventions

  • E-106-2006
  • E-226-2014           TAB-4198
    Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer

Patents

  • US
    Provisional (PRV) 62/084,654
    Filed on 2014-11-26
    Status: Abandoned
  • Patent Cooperation Treaty
    Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/062269
    Filed on 2015-11-24
    Status: Expired
  • Australia
    National Stage 2015353720
    Filed on 2015-11-24
    Status: Issued
  • Canada
    National Stage 2968399
    Filed on 2015-11-24
    Status: Pending
  • China
    National Stage 201580070673.7
    Filed on 2015-11-24
    Status: Issued
  • European Patent
    National Stage 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Israel
    National Stage 252258
    Filed on 2017-05-14
    Status: Issued
  • Japan
    National Stage 2017-527874
    Filed on 2015-11-24
    Status: Issued
  • South Korea
    National Stage 10-2017-7017289
    Filed on 2017-06-23
    Status: Issued
  • Mexico
    National Stage MX/a/2017/006865
    Filed on 2015-11-24
    Status: Issued
  • New Zealand
    National Stage 732045
    Filed on 2017-05-18
    Status: Issued
  • Saudi Arabia
    National Stage 517381608
    Filed on 2015-11-24
    Status: Issued
  • Singapore
    National Stage 11201704155U
    Filed on 2015-11-24
    Status: Issued
  • US Patent 11,207,394
    Filed on 2017-05-23
    Status: Issued
  • Hong Kong
    European patent (EP) 18103250.9
    Filed on 2018-03-07
    Status: Issued
  • European Patent
    Divisional (DIV) 20150279.6
    Filed on 2020-01-03
    Status: Issued
  • Singapore
    Divisional (DIV) 10201913978R
    Filed on 2019-12-31
    Status: Pending
  • Austria
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Belgium
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Switzerland
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Czech Republic
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Germany
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Spain
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • France
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • United Kingdom
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Greece
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Ireland
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Italy
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • The Netherlands
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Norway
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Poland
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Portugal
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Sweden
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Slovenia
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Slovakia
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Turkey
    European patent (EP) 15807756.0
    Filed on 2015-11-24
    Status: Issued
  • Australia
    Divisional (DIV) 2020203465
    Filed on 2020-05-26
    Status: Issued
  • Saudi Arabia
    Divisional (DIV) 520420365
    Filed on 2020-10-15
    Status: Pending
  • Hong Kong
    European patent (EP) 42020021375.9
    Filed on 2020-12-01
    Status: Issued
  • Japan
    Divisional (DIV) 2021-063092
    Filed on 2021-04-01
    Status: Issued
  • China
    Divisional (DIV) 202111263859.8
    Filed on 2021-10-27
    Status: Issued
  • US Patent 12,312,391
    Filed on 2021-11-24
    Status: Issued
  • Hong Kong
    China Patent (CN) 42022054674.1
    Filed on 2022-06-07
    Status: Issued
  • Australia
    Divisional (DIV) 2023200614
    Filed on 2023-02-07
    Status: Pending

Collaborations

  • Licensing
Date Published